NCT03348527 - A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

October 30, 2020

Study Completion Date

November 30, 2020

Conditions

Prostate Cancer

Interventions

DRUG

2-Hydroxyflutamide Depot

Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide

Trial Locations (10)

Hospital of Lithuanian University of Health Sciences, Kaunas

Nova Scotia Health Authority, Halifax

Jonathan Giddens Medicine Professional Corporation, Brampton

G. Kenneth Jansz Medicine Professional Corporation, Burlington

The Fe/Male Health Centres, Oakville

Sunnybrook Health Sciences Centre, Toronto

CIUSSS de l'Estrie - CHUS, Sherbrooke

Helsinki University Hospital, Helsinki

Tampere University Hospital, Tampere

National Cancer Institute - Oncourology Department, Vilnius